Adverse effects by frequency for use of valproate semisodium.[1][2][3]

Very common (>10% frequency)[edit | edit source]

  • Nausea
  • Tremor

Common (1-10% frequency)[edit | edit source]

Uncommon (0.01-0.1% frequency)[edit | edit source]

Rare (<0.01% frequency)[edit | edit source]

Notes[edit | edit source]

  1. ↑ 1.0 1.1 1.2 1.3 Rare cases of lethargy occasionally progressing to stupor, sometimes with associated hallucinations or convulsions have been reported. Encephalopathy and coma have very rarely been observed. These cases are most often seen in association with other factors such as rapid dose escalations or withdrawal from other medications. They have usually been reversible on withdrawal of treatment or reduction of dosage.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 These cases most commonly occur in the paediatric population.
  3. ↑ Weight gain should be monitored closely as there is a potential link between weight gain and polycystic ovary syndrome.

References[edit | edit source]

  1. ↑ "Depakote 250mg Tablets - Summary of Product Characteristics". electronic Medicines Compendium. Sanofi. 28 November 2013. Archived from the original on 1 February 2014. Retrieved 18 January 2014.
  2. ↑ "DEPAKOTE (divalproex sodium) tablet, delayed release [AbbVie Inc.]". DailyMed. AbbVie Inc. September 2013. Archived from the original on 12 November 2013. Retrieved 18 January 2014.
  3. ↑ "Depakote (divalproex sodium) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 2 February 2014. Retrieved 18 January 2014.